Micrus Endovascular Corporation (Nasdaq: MEBD) $17.28. Today reported financial results for the three and nine months ended December 31, 2009 and raised fiscal 2010 revenue guidance. Total revenues increased 24% for the third quarter (or 20% in constant currencies) compared with the same period last year. Operating income was $3.4 million for the third quarter, compared with an operating loss of $1.7 million for the prior-year period; operating income for the first nine months was $7.4 million, compared with an operating loss of $10.6 million for the prior-year period. Cash and cash equivalents as of December 31, 2009 were $28.6 million, up $11.6 million from March 31, 2009.
Net income for the third quarter of fiscal 2010 was $3.3 million, or $0.20 per diluted share on 16.8 million weighted-average shares outstanding, and included $1.5 million or $0.09 per diluted share of non-cash stock-based compensation expense. The net loss for the third quarter of fiscal 2009 was $2.3 million, or $0.15 per share on 15.7 million weighted-average shares outstanding, and included $1.2 million or $0.08 per share of non-cash stock-based compensation expense.
To read more about Micrus Endovascular visit http://www.smallcapreview.com/mend.htm
What They Do: Micrus develops, manufactures and markets implantable and disposable medical devices for use in the treatment of cerebral vascular diseases.
EarthLink, Inc. (Nasdaq: ELNK) $8.18. Today announced financial results for its fourth quarter and full year ended December 31, 2009. Highlights for the fourth quarter include: Net income of $193.3 million or $1.79 per share. Dividend payments to shareholders of $15.0 million. Announced full year 2010 Adjusted EBITDA (a non-GAAP measure) guidance of $180 million to $190 million.
EarthLink reported revenue of $164.5 million in the fourth quarter and $723.7 million for the full year 2009, representing a 24 percent decline from both the fourth quarter of 2008 and the full year 2008. The pace of EarthLink's sequential revenue decline continued to attenuate, with revenue down 6 percent from the third quarter of 2009. Broadband comprised 58% of EarthLink's revenue in the fourth quarter of 2009, up from 54% in the year-ago quarter.
Net income was $193.3 million, or $1.79 per share, in the fourth quarter of 2009 and $287.1 million, or $2.66 per share, for the full year 2009; as compared to $24.4 million, or $0.22 per share in the fourth quarter of 2008, and $178.6 million, or $1.61 per share for the full year 2008.
What They Do: EarthLink is a leading Internet service provider.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) %7.23. Today announced financial results for the fourth quarter and year ended December 31, 2009.
For the three months ended December 31, 2009, total revenues were $54.9 million compared to $34.2 million for the three months ended December 31, 2008. This increase was driven by $22.9 million in product sales, primarily the $22.5 million order of 10,000 courses of intravenous (i.v.) peramivir from the Department of Health and Human Services (HHS), as well as the $7.0 million milestone payment from the Company's partner, Shionogi & Co., Ltd., related to its filing of a New Drug Application (NDA) to seek regulatory approval for i.v. peramivir in Japan.
Net income for the fourth quarter of 2009 was $15.2 million, or $0.37 per basic share and $0.35 per diluted share, compared to net income of $10.1 million, or $0.26 per share for the fourth quarter of 2008.
What They Do: BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/. To follow us on Twitter visit http://twitter.com/SmallCapReview.
